Survivorship – Adult Primary Bone Sarcoma MDAnderson


Page 1 of 6

Making Cancer History®

THE UNIVERSITY OF TEXAS

Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



NED = no evidence of disease

¹GCC should be initiated by the **Primary Oncologist**. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The Advance Care Planning (ACP) note should be used to document GCC discussion. Refer to GCC home page (for internal use only).

Survivorship – Adult Primary Bone Sarcoma

Making Cancer History®

THE UNIVERSITY OF TEXAS

MDAnderson

Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY	CONCURRENT COMPONENTS		DISPOSITION
Primary Bone Sarcoma 5 years Post-Treatment and NED	OF VISIT MONITORING FOR LATE EFFECTS	 Assess for: CBC with differential and comprehensive metabolic panel (CMP) if treated with chemotherapy Cardiotoxicity as clinically indicated (see Survivorship – Adult Cardiovascular Screening algorithm) Renal dysfunction/Nephrotoxicity Second malignancy Musculoskeletal problems Limb salvage patients: assess for prosthetic/mechanical failure and/or prosthetic infection Fit, condition of external prosthesis, and document the K-level¹ for ampute patients Ototoxicity annually for patients who received cisplatin or carboplatin therapy; audiology referral for hearing loss, tinnitus, or abnormal pure tone audiometry results showing a loss > 15 dB absolute threshold level (1,000-8,000 Hz) Fertility/sexual health Breast cancer screening if previously treated with radiation Adult: Annual breast screening 8-10 years post radiation treatment to the chest/axilla or at age 40 years; whichever comes first (see Breast Cancer Screening algorithm) Annual MRI breast (bilateral) in addition to screening mammography for patients who received irradiation to the chest between the ages of 10 and 30 years old Pediatric: Annual breast screening post radiation treatment to the chest/axilla/TBI beginning at puberty until age 25 years; then every 6 months Annual MRI breast and screening mammography 8 years post radiation treatment or at age 25 years; whichever occurs last 	Refer or consult as indicated

NED = no evidence of disease

TBI = total body irradiation

¹K-level is a rating system used by the Centers for Medicare & Medicaid Services (CMS) to indicate the patient's rehabilitation potential and intended use of the lower limb prosthesis

Page 2 of 6


Survivorship – Adult Primary Bone Sarcoma MDAnderson Cancer Center

Page 3 of 6

Making Cancer History®

THE UNIVERSITY OF TEXAS

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



AYA = Adolescent & Young Adult NED = no evidence of disease

¹ See Physical Activity, Nutrition, Obesity Screening and Management and Tobacco Cessation Treatment algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

² Includes breast, cervical, colorectal, liver, lung, pancreatic, prostate, and skin cancer screening

³ Administer antibiotic 1 hour prior to invasive dental procedure for patients with mega prosthetic reconstruction (e.g. joint replacements in limb salvage patients). Antibiotic options are cephalexin 2 g PO or clindamycin 600 mg PO if patient has an allergy to penicillin or cephalosporin.

Based on American Society of Clinical Oncology (ASCO) guidelines

Survivorship – Adult Primary Bone Sarcoma MDAnderson Cancer Center

Page 4 of 6

Making Cancer History[®]

THE UNIVERSITY OF TEXAS

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

American Academy of Orthopaedic Surgeons. (2012). Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures. Evidence-Based Clinical Practice Guideline. Retreaved from: https://www.aaos.org/globalassets/quality-and-practice-resources/dental/pudp_guideline.pdf

- Bishop, M. W., Ness, K. K., Li, C., Liu, W., Srivastava, D. K., Chemaitilly, W., ... Mulrooney, D. A. (2020). Cumulative burden of chronic health conditions in adult survivors of osteosarcoma and Ewing sarcoma: A report from the St. Jude Lifetime Cohort Study. Cancer Epidemiology, Biomarkers, & Prevention, 29(8), 1627-1638. doi:10.1158/1055-9965.EPI-20-0076
- Chow, E. J., Aggarwal, S., Doody, D. R., Aplenc, R., Armenian, S. H., Baker, K. S., ... Lipshultz, S. (2023). Dexrazoxane and long-term heart function in survivors of childhood cancer. Journal of Clinical Oncology, 41(12), 2248-2257. doi:10.1200/JCO.22.02423
- Cipriano, C., Griffin, A. M., Ferguson, P. C., & Wunder, J. S. (2017). Developing an evidence-based followup schedule for bone sarcomas based on local recurrence and metastatic progression. Clinical Orthopaedics and Related Reasearch, 475(3), 830-838. doi:10.1007/s11999-016-4941-x
- Cipriano, C. A., Jang, E., & Tyler, W. (2020). Sarcoma surveillance: A review of current evidence and guidelines. Journal of the American Academy of Orthopaedic Surgeons, 28(4), 145-156. doi:10.5435/JAAOS-D-19-00002
- Farry, J. K., Flombaum, C. D., & Latcha, S. (2012). Long term renal toxicity of ifosfamide in adult patients 5 year data. European Journal of Cancer, 48(9), 1326-1331. doi:10.1016/i.eica.2012.03.009
- Franzoi, I. G., Granieri, A., Sauta, M. D., Agnesone, M., Gonella, M., Grimaldi, C., ... Comandone, A. (2023). The psychological impact of sarcoma on affected patients. Psycho-Oncology, 32(12), 1787-1797. doi:10.1002/pon.6240
- Fu, P., Shi, Y., Chen, G., Fan, Y. Gu, Y., & Gao, Z. (2020). Prognostic factors in patients with osteosarcoma with the surveillance, epidemiology, and end results database. Technology in Cancer Research & Treatment, 19. doi:10.1177/1533033820947
- Goedhart, L. M., Ho, V. K.Y., Ploegmakers, J. J. W., van der Geest, I. C. M., van de Sande, M. A. J., Bramer, J. A., ... Jutte, P. C. (2022). Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment. Journal of Bone Oncology, 38, 100466. doi:10.1016/j.jbo.2022.100466
- Hesla, A. C., Discacciati, A., Tsagkozis, P., & Smedby, K. E. (2020). Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based stud. British Journal of Cancer, 122, 1242-1249. doi:10.1038/s41416-020-0748-3
- Hua, K. C., & Hu, Y. C. (2020). Treatment method and prognostic factors of chondrosarcoma: Based on surveillance, epidemiology, and end results (SEER) database. Translational Cancer Research, 9(7), 4250-4266. doi:10.21037/tcr-20-357
- Kamboj, M., Bohlke, K., Baptiste, D.M., Dunleavy, K., Fueger, A., Jones, A.L., ... Kohn, E.C. (2024). Vaccination of Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology, 42(14), 1699-1721. doi:10.1200/JCO.24.00032
- Kube, S. J., Blattmann, C., Bielack, S. S., Kager, L., Kaatsch, P., Kühne, T., ... Berß, J. W. O. (2022). Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults. Cancer, 128(9), 1787-1800. doi:10.1002/cncr.34110
- Latcha, S., Jaimes, E. A., Patil, S., Glezerman, I. G., Mehta, S., & Flombaum, C.D. (2016). Long-term renal outcomes after Cisplatin treatment. Clinical Journal of the American Society of Nephrology, 11(7), 1173-1179. doi:10.2215/CJN.08070715

Survivorship – Adult Primary Bone Sarcoma MDAnderson Cancer Center

Page 5 of 6

Making Cancer History*

THE UNIVERSITY OF TEXAS

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

- Lipshultz, E. R., Holt, G. E., Ramasamy, R., Yechieli, R., & Lipshultz, S. E. (2017). Fertility, cardiac, and orthopedic challenges in survivors of adult and childhood sarcoma. American Society of Clinical Oncology Educational Book. 37, 799-806. doi:10.1200/EDBK 17470
- Marina, N. M., Liu, Q., Donaldson, S. S., Sklar, C. A., Armstrong, G. T., Oeffinger, K. C., ... Ness, K. K. (2017). Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. Cancer, 123(13), 2551-2560. doi:10.1002/cncr.30627
- MD Anderson Institutional Policy #CLN1202 Advance Care Planning Policy. Advance Care Planning (ACP) Conversation Workflow (ATT1925)
- Mo, Z., Deng, Y. M. Bao, Y. Liu, J., & Jiang, Y. (2023). Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience. Cancer Medicine, 12(24), 21709-21724. doi:10.1002/cam4.6730
- National Comprehensive Cancer Network (2024). Bone Cancer (NCCN Guideline Version 2.2024). https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf Retrieved from https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418
- Quartuccio, N., Fox, J., Kuk, D., Wexler, L. H., Baldari, S., Cistaro, A., & Schöder, H. (2014). Pediatric bone sarcoma: Diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up. American Journal of Roentgenology, 204(1). doi:10.2214/AJR.14.12932
- Schiavetti, A., Pedetti, V., Varrasso, G., Marrucci, O., Celani, C., Andreoli, G., & Bonci, E. (2018). Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience. Pediatric Hematology and Oncology, 35(3), 167-176. doi:10.1080/08880018.2018.1476941
- Shamai, S., Rozenbaum, Z., Merimsky, O., Derakhshesh, M., Moshkovits, Y., Arnold, J., ... Laufer-Perl, M. (2020). Cardio-toxicity among patients with sarcoma: A cardio-oncology registry. BMC Cancer, 20(1), 609. doi:10.1186/s12885-020-07104-9
- Stachelek, G. C., Ligon, J. A., Vogel, J., Levin, A. S., Llosa, N. J., Ladle, B. H., ... Pratilas, C. A. (2021). Predictors of recurrence and patterns of initial failure in localized Ewing sarcoma: A contemporary 20-year experience. Sarcoma, 2021, 6681741, doi:10.1155/2021/6681741
- Stanborough, R., Demertzis, J. L., Wessell, D. E., Lenchik, L., Ahlawat, S., Baker, J. C., ... Beaman, F. D. (2022). ACR Appropriateness Criteria® malignant or aggressive primary musculoskeletal tumor-staging and surveillance: 2022 update. Journal of the American College of Radiology, 19(11), S374-S389. doi:10.1016/j.jacr.2022.09.015
- Stokke, J., Sung, L., Gupta, A., Lindberg, A., & Rosenberg, A. R. (2015). Systemic review and meta-analysis of objective and subjective quality of life among pediatric, adolescent, and young adult bone tumor survivors. Pediatric Blood & Cancer, 62(9), 1616-1629. doi:10.1002/pbc.25514
- Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., ... Stacchiotti, S. (2021). Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 32(12), 1520-1536. doi:10.1016/j.annonc.2021.08.1995

MDAnderson Survivorship – Adult Primary Bone Sarcoma Cancer Center

Making Cancer History®

THE UNIVERSITY OF TEXAS

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This survivorship algorithm is based majority expert opinion of the Sarcoma Survivorship workgroup at The University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Lead

Valerae O. Lewis, MD (Orthopaedic Oncology) Michael Nakazawa, MD, PhD (Sarcoma Medical Oncology) Janie Rutledge, MSN, APRN, ANP (Orthopaedic Oncology) Christopher Scally, MD (Surgical Oncology)

Workgroup Members

Olga N. Fleckenstein, BS⁺ Yimin Geng, MS, MSLIS (Research Medical Library) Katherine Gilmore, BA, MPH (Cancer Survivorship) Richard Gorlick, MD (Pediatrics) Thoa Kazantsev, MSN, RN, OCN[◆] Bryan Moon, MD (Orthopaedic Oncology) Kristi Mungovan, MS (Surgical Oncology) Johnny L. Rollins, MSN, APRN, ANP-C (Cancer Survivorship) Michael Roth, MD (Pediatrics) Whittney Thoman, MS (Cancer Survivorship) Valerie Villanueva, RN (Sarcoma Medical Oncology)

[•]Clinical Effectiveness Development Team

Page 6 of 6